

Vahid Afshar-Kharghan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8574997/publications.pdf>

Version: 2024-02-01

46
papers

3,246
citations

304743

22
h-index

276875

41
g-index

46
all docs

46
docs citations

46
times ranked

4855
citing authors

#	ARTICLE	IF	CITATIONS
1	Paraneoplastic Thrombocytosis in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 610-618.	27.0	651
2	The Platelet Lifeline to Cancer: Challenges and Opportunities. <i>Cancer Cell</i> , 2018, 33, 965-983.	16.8	390
3	Platelet activation leads to activation and propagation of the complement system. <i>Journal of Experimental Medicine</i> , 2005, 201, 871-879.	8.5	353
4	Platelets increase the proliferation of ovarian cancer cells. <i>Blood</i> , 2012, 120, 4869-4872.	1.4	190
5	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. <i>Nature Communications</i> , 2017, 8, 310.	12.8	169
6	Autocrine Effects of Tumor-Derived Complement. <i>Cell Reports</i> , 2014, 6, 1085-1095.	6.4	164
7	Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1392-1398.	2.0	161
8	Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. <i>Blood</i> , 2014, 124, 184-187.	1.4	137
9	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. <i>Journal of Clinical Investigation</i> , 2016, 126, 1885-1896.	8.2	101
10	Role of ADP receptors on platelets in the growth of ovarian cancer. <i>Blood</i> , 2017, 130, 1235-1242.	1.4	86
11	von Willebrand factor is a cofactor in complement regulation. <i>Blood</i> , 2015, 125, 1034-1037.	1.4	73
12	Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. <i>Blood</i> , 2013, 122, 1487-1493.	1.4	72
13	Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 602-610.	7.0	72
14	Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial to Mesenchymal Transition. <i>Journal of Immunology</i> , 2016, 196, 1412-1418.	0.8	66
15	Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14266-14271.	7.1	61
16	Role of Platelet-Derived Tgf β 21 in the Progression of Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5611-5621.	7.0	51
17	Platelet Effects on Ovarian Cancer. <i>Seminars in Oncology</i> , 2014, 41, 378-384.	2.2	48
18	The Interaction between Factor H and Von Willebrand Factor. <i>PLoS ONE</i> , 2013, 8, e73715.	2.5	45

#	ARTICLE	IF	CITATIONS
19	Atypical hemolytic uremic syndrome. Hematology American Society of Hematology Education Program, 2016, 2016, 217-225.	2.5	44
20	Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer. Science Advances, 2021, 7, .	10.3	43
21	OvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer. Blood Advances, 2020, 4, 3329-3342.	5.2	33
22	Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. BBA Clinical, 2016, 6, 76-81.	4.1	26
23	Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. Journal of Thrombosis and Haemostasis, 2022, 20, 104-114.	3.8	23
24	Complement and clot. Blood, 2017, 129, 2214-2215.	1.4	21
25	The interaction between the complement system and hemostatic factors. Current Opinion in Hematology, 2020, 27, 341-352.	2.5	20
26	A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets. Platelets, 2017, 28, 99-102.	2.3	18
27	Complement activation in thrombotic microangiopathies. British Journal of Haematology, 2013, 160, 404-406.	2.5	17
28	Role of tissue-factor bearing extracellular vesicles released from ovarian cancer cells in platelet aggregation in vitro and venous thrombosis in mice. Thrombosis Update, 2021, 2, 100020.	0.9	15
29	Platelets are not hyperreactive in patients with ovarian cancer. Platelets, 2016, 27, 716-718.	2.3	14
30	Hyperadhesive von Willebrand Factor Promotes Extracellular Vesicle-Induced Angiogenesis. JACC Basic To Translational Science, 2022, 7, 247-261.	4.1	13
31	Platelets Increase the Expression of PD-L1 in Ovarian Cancer. Cancers, 2022, 14, 2498.	3.7	12
32	The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer. Blood Advances, 2021, 5, 1947-1951.	5.2	10
33	The Provocative Roles of Platelets in Liver Disease and Cancer. Frontiers in Oncology, 2021, 11, 643815.	2.8	10
34	Kidney Injury in Murine Models of Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1920-1924.	2.0	6
35	Bleeding Risk in Thrombocytopenic Cancer Patients with Venous Thromboembolism (VTE) Receiving Anticoagulation. Blood, 2012, 120, 3408-3408.	1.4	6
36	Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer and Metastasis Reviews, 2022, 41, 147-172.	5.9	6

#	ARTICLE	IF	CITATIONS
37	COMPLEMENTing the diagnosis of aHUS. Blood, 2014, 124, 1699-1700.	1.4	5
38	Heparin-induced thrombocytopenia among patients of a comprehensive cancer center. SAGE Open Medical Case Reports, 2014, 2, 2050313X1453394.	0.3	5
39	Novel markers for liquid biopsies in cancer management: Circulating platelets and extracellular vesicles. Molecular Cancer Therapeutics, 2022, , .	4.1	5
40	Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. Frontiers in Oncology, 2015, 5, 29.	2.8	3
41	APC ameliorates pulmonary complications in cGVHD. Blood, 2019, 134, 724-725.	1.4	1
42	Losing control to bad relatives. Blood, 2021, 137, 3462-3463.	1.4	0
43	Factor H Binds to Von Willebrand Factor (VWF) and Regulates Its Cleavage by ADAMTS-13. Blood, 2008, 112, 3935-3935.	1.4	0
44	Reduced GVHD in C3-Deficient Mice Is Associated with a Decrease in Donor Th1/Th17 Polarization and Recipient Th1- Driven Dendritic Cell Activation. Blood, 2011, 118, 308-308.	1.4	0
45	Platelet Function in Ovarian Cancer. Blood, 2015, 126, 4656-4656.	1.4	0
46	Erythropoietin and hepatocellular carcinoma: What is patients survival outcome?. Journal of Clinical Oncology, 2017, 35, e15660-e15660.	1.6	0